Argentine Registry of Crohn's Disease and Ulcerative Colitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGrupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa
About this trial
RADECCU is a strictly observational IBD registry in Argentina. The registry is open to all practicing gastroenterologist in the country grouped within the Argentinean Crohn's and Ulcerative Colitis Group (GADECCU). The registry will include outcomes of routine clinical practice of patients with IBD including the pediatric and adult population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Any patient diagnosed with IBD defined by validated diagnostic criteria can be included into the registry. The criteria for IBD diagnosis were based on previously published criteria for IBD diagnosis, including clinical, endoscopic, laboratory, and histopathological aspects, as well as small bowel imaging studies
Disqualifiers
Suspected IBD diagnosis without confirmation
IBD patients with incomplete information about therapy and follow-up
Trial population
Target population: Any patient diagnosed with IBD defined by validated diagnostic criteria. In order to ensure the inclusion of all IBD patients in Argentina, the executive committee invites all centers associated to GADECCU and involved in the management of IBD patients, regardless of the volume of patients they are in charge of, including both public and private centers. To reduce the possibility of selection bias, each participating physician from each center should aim to include all patients seen in their practice or clinic.
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
observational study
Other interventionObservational registry without clinical interventions
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Demography
Information from IBD patients in terms of demographic, clinical and diagnostic aspects
Time frame
Observational from July-2023Secondary outcomes
1
Safety aspects of IBD patients
Safety aspects, including infections, and access to healthcare
Time frame
Observational from July-2023Other outcomes
1
Therapy efectiveness
For the treatment effectiveness outcome, information about IBD complications as flares, need of hospitalization and surgery will be included
Time frame
Observational from July-2023Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov